A Phase 1 interventional study of Paliperidone palmitate in Schizophrenia, sponsored by Janssen Pharmaceutical K.K.. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-09-16.
Sponsored by Janssen Pharmaceutical K.K. · Phase 1, Interventional, and Treatment
The purpose of this study is to evaluate the pharmacokinetics (study of what the body does to a drug) and safety of paliperidone palmitate ranging from 75 to 150 milligram equivalents in repeated doses (4 injections) administered in the deltoid muscle (muscle in the shoulder) or gluteal muscle (group of muscles present in the buttocks) in participants with schizophrenia.
This is a multicenter (study conducted at multiple sites), open label (all people know the identity of the intervention), randomized (the study medication is assigned by chance), parallel-group (each group of participants will be treated at the same time) study. Approximately, 60 participants will be enrolled in the study. This study will consist of a screening phase (maximum 14 days), an observation phase (92 days), and a follow-up phase (98 days). Participants will be randomly assigned to treatment group A, B, or C. During the observation phase, participants will receive injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in the deltoid muscle or gluteal muscle as applicable on Days 1, 8, 36, and 64 alternating between sides (left/right). Safety evaluations will include assessment of adverse events, clinical laboratory tests, electrocardiogram, vital signs, physical examination, injection site reaction, drug-induced extrapyramidal symptoms scale, and visual analog scale which will be evaluated throughout the study. The total study duration for each participant will be approximately 190 days.
3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.
This study's enrollment of 76 is close to the median of 70 across 2,872 interventional studies indexed under Schizophrenia.
Browse Schizophrenia studies →Janssen Pharmaceutical K.K. is the lead sponsor of 122 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 6 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:- Participants had to have the capability to provide informed consent in writing to participate in the study
Exclusion Criteria:- DSM-IV-TR diagnosis other than schizophrenia
Participants will receive 4 injections of paliperidone palmitate 150 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
Drug: Paliperidone palmitate
Participants will receive 4 injections of paliperidone palmitate 75 milligram in the deltoid muscle on Days 1, 8, 36, and 64.
Drug: Paliperidone palmitate
Participants will receive 4 injections of paliperidone palmitate 75 milligram in the gluteal muscle on Days 1, 8, 36, and 64.
Drug: Paliperidone palmitate
Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
Also known as: JNS010
Plasma concentration of unchanged drug (Paliperidone palmitate)
Time frame: Days 1 to 190
Plasma concentration of active metabolite (paliperidone)
Time frame: Days 1 to 190
Plasma concentration of enantiomer of paliperidone palmitate (R078543)
Time frame: Days 1 to 190
Plasma concentration of enantiomer paliperidone palmitate (R078544)
Time frame: Days 1 to 190
Maximum Observed Plasma Concentration (Cmax) of paliperidone palmitate
The Plasma Concentration (Cmax) is defined as maximum observed analyte concentration.
Time frame: Days 1 to 190
Time to Reach Maximum Observed Plasma Concentration (Tmax) of paliperidone palmitate
The Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
Time frame: Days 1 to 190
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of paliperidone palmitate
The Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) is a measure of the plasma paliperidone concentration from time zero to end of dosing interval. It is used to characterize drug absorption.
Time frame: Days 1 to 190
Number of participants with adverse events
Time frame: Up to Day 190
Change from baseline in Positive and Negative Syndrome Scale for Schizophrenia (PANSS)
The PANSS is a medical scale that assesses various symptoms of schizophrenia. The symptoms are rated on a 7-point scale from 1 (absent) to 7 (extreme psychopathology). The total score is the sum of all 30 PANSS items, with a range of 30 (absent) to 210 (extreme ill). Higher scores indicate worsening.
Time frame: Screening, Baseline (Day 1), Days 8, 36, 64, and 92
Change From Baseline in Clinical Global Impression Severity (CGI-S) Scale Score
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.
Time frame: Screening, Baseline (Day 1), Days 8, 36, 64, and 92
No study locations are listed for this record.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Pharmaceutical K.K.